During 1981-89 period, Dr George Zhu’s interests were focused on Haemostasis and Thrombosis in clinics. In 1984 he successfully completed his rescuing two patients with severe prothrombin(factor II)deficiency.One of two the blood clot time was remarkably prolonged over 16 hours. Moreover It’s much interesting that in this female baby the cause of vitk deficiency might be the breast feed problem(nutrition deficiency)and/or poor absorption from bowel. He also highlighted in the important mechanism anti-penicillin antibodies as to penicillin-induced hemolytic anemia,in hemophilia and in acquired amegakaryocytic thrombocytopenia purpura. In 1989 he completed Master of medicine under the help of Professor RM Bertina and AW Broekmans at Haemostasis and Thrombosis Research Unit of University Hospital Leiden in The Netherlands,his studies are designed to investigate some aspects of intravascular coagulation in acute leukemias. And specifically in the area of human plasma protein C.The abstracts published in Thrombosis and Haemostasis 62:391,572,1989.

After having received his Master of medicine, he was intensively fresh insights into tumor molecular biology and pharmacology. In 1989-91,he postulate oncogenic receptor hypothesis,as a result of his experiments in which oncogenic pml/RARA fusion receptor(an RAR mutant)gene rearranged within t(15;17)translocation in acute promyelocytic leukemia;and androgen cognating with its(androgen receptor AR /estrogen receptor ERa or FGFR-1)receptor induced tumors of the breast glands in an aplastic anemia during the course of testosterone treatment. He is the inventor of oncogenic receptor. He is the pioneer of this research work. Due to his hypothesis(EGF receptor in stimulating cellular proliferation and differentiation, he also realized very early(1989-91)that epidermal growth factor(EGF)is an important medical drug in wound healing and in the role of cosmetics area(China patent application No.201710144050.0).He is exploring the problems of gene regulation of retinoic acid action(Retinoid Pharmacology. Oncogenic pml/RARa in APL is a constitutive transcriptional repressor to differentiation block at the promyelocytic stage, whereas retinoic acid overcome the transcriptional repressor activity of pml/RARa and induce promyelocytes maturation. This molecular mechanism of retinoic acid is the mimicry of “lac operon” in some ways,which is first to described in eukaryotes. All data above, Dr George Zhu believes that his work is unique.

Drug Discovery, Medical Oncology, and Targeting oncogenic receptors in tumours



Affiliation: Tehran University of Medical Sciences, Tehran, Iran.

E-mail: sansan4240732@163.com